Stocktoria
Pluri Inc. PLUR
Pluri Inc. (PLUR) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $1.3M at a -1690.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| PLUR | Pluri Inc. | 2/9 | — | — | — |
| SCNI | Scinai Immunotherapeutics Ltd. | 2/9 | — | — | — |
| OTLK | Outlook Therapeutics, Inc. | 1/9 | — | — | — |
| PROK | PROKIDNEY CORP. | 1/9 | — | — | — |
| IMA | ImageneBio, Inc. | 3/9 | 5.55 | — | — |
| HUMA | Humacyte, Inc. | 3/9 | — | — | — |
| CRDF | Cardiff Oncology, Inc. | 2/9 | — | — | — |
About Pluri Inc.
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. Its product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. The company also offers cell manufacturing services and cell-based coffee; and develops and commercializes cultivated meat products. It operates in the field of regenerative medicine, food tech, immunotherapy, CDMO, and AgTech. It has collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
FAQ
Is PLUR financially healthy?
Pluri Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does PLUR pay a dividend?
No, Pluri Inc. does not currently pay a dividend.
How profitable is PLUR?
In FY2025, Pluri Inc. had a net margin of -1690.3%.
Is PLUR a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Pluri Inc.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-06-30. Facts plus Stocktoria's own computed scores — not investment advice.